REPL — Replimune Group, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1737953 ·
Last close
$13.24
Market Cap
$1.25B
52W High
$16.33
52W Low
$1.50
ADV30
2,288,820
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -67,951,000 | — | 252,447,000 | 185,359,000 | 146,802,000 |
| Mar 2026 | 0 | — | -72,872,000 | -73,217,000 | 332,388,000 | 209,024,000 | 166,228,000 |
| Dec 2025 | 0 | — | -71,527,000 | -70,930,000 | 333,590,000 | 122,951,000 | 123,051,000 |
| Sep 2025 | 0 | — | -83,914,000 | -83,100,000 | 389,450,000 | 102,298,000 | 126,114,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-280,344,000
Investing CF
$310,843,000
Financing CF
$66,294,000
CapEx
$-4,223,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.41
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,262,519,000
Inventory
—
Receivables
$1,619,000
ST Investments
$59,865,000
EBIT TTM
$-305,632,000
Pretax Income TTM
$-314,491,000
Interest Exp TTM
$8,859,000
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | -318,315,000 | -313,940,000 | 332,388,000 | 166,228,000 | 166,160,000 | -280,344,000 |
| Mar 2025 | 0 | -259,854,000 | -247,297,000 | 551,328,000 | 135,485,000 | 415,843,000 | -192,250,000 |
| Mar 2024 | 0 | -232,853,000 | -215,794,000 | 487,722,000 | 113,214,000 | 374,508,000 | -185,467,000 |
| Mar 2023 | 0 | -174,166,000 | -174,284,000 | 646,591,000 | 91,299,000 | 555,292,000 | -128,050,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-172,891,000
OpCashFlow TTM
$0
Assets (Latest)
$551,328,000
Forward EPS
$-2.04
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $10.00 · spot: $13.24 · call volume: 270 · put volume: 249
Expected Move to 2027-01-15:
±$5.30
(40.03%) —
implied range
$7.94 –
$18.54
· ATM straddle on $13.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMTX | Immatics N.V. | $1.34B | $8.78 | — |
| VOR | Vor Biopharma Inc. | $1.13B | $19.08 | — |
| COAG | Hemab Therapeutics Holdings, Inc. | $1.44B | $30.84 | — |
| ODTX | Odyssey Therapeutics, Inc. | $1.07B | $22.22 | — |
| INBX | Inhibrx Biosciences, Inc. | $1.47B | $100.08 | — |
News headlines (Yahoo Finance, 1h cache)
Replimune to Present at the Cantor Global Healthcare Conference 2026
2026-09-03 12:00 · Yahoo
Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today?
2026-08-27 03:13 · Yahoo
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-19 20:01 · Yahoo
Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update
2026-08-14 12:00 · Yahoo
Replimune Group (REPL) Wins FDA Approval For Advanced Melanoma Treatment
2026-08-13 22:14 · Yahoo
REPL Stock Hits Near 18-Month High On Pricing Of $150M Offering – But, Retail Sees Share Price ‘Unwinding Over Time’
2026-08-10 16:21 · Yahoo
Replimune’s First Commercial Drug Arrives—With A 2027 Cash Cliff And 2030 Finish Line
2026-08-08 00:31 · Yahoo
Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling.
2026-08-07 19:33 · Yahoo
REPL Stock Slumps 11% After-Hours — What’s Driving The Selloff?
2026-08-06 21:37 · Yahoo
Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen
2026-08-06 20:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.